Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy 2024-11-19 07:40
Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients 2024-10-25 07:40
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine 2024-10-22 07:40
Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy 2024-10-21 07:40
Everest Medicines Announces Interim Results for First Half of 2024 2024-08-28 08:00
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 2024-08-22 08:00
Everest Medicines to Announce 2024 Interim Results on August 28, 2024 2024-08-06 07:30
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis 2024-07-22 09:00
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration 2024-07-18 08:00
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis 2024-07-15 13:44
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China 2024-05-14 21:41
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau 2024-05-08 08:05
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients 2024-05-02 09:23
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 2024-03-28 07:01
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients 2024-03-20 09:16
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer 2024-03-18 09:00
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® 2024-03-12 09:28
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau 2024-03-11 09:00
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 2024-03-06 08:59
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis 2024-02-27 07:14
1 2 3 4 5 7